Fig. 3 | Scientific Reports

Fig. 3

From: Low serum neopterin early indicates durable benefits of atezolizumab and pembrolizumab therapy in advanced lung cancer

Fig. 3

Forest plots for the univariable Cox regression analysis for a) progression-free survival (PFS) and b) time to treatment failure (TTF) among NSCLC patients treated with the anti-PD-1/PD-L1 drugs. Low-NEO status was defined as serum neopterin concentrations ≤ 71.65 nM at the end of the 3rd cycle (NEO.3) and ≤ 66.84 nM at the end of the 4th cycle (NEO.4). Data are presented as hazard ratios, HR (markers) along with their 95% confidence intervals (whiskers).

Back to article page